Prelude sells final stake in Oxford Biomedica

Prelude Trust has completed the sale of its remaining shareholding in Oxford Biomedica Plc. The institution has now realised a total of £5m through the sale of its shareholding between 2003 and 2005. Oxford BioMedica is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The company was established in 1995 as a spinout from Oxford University. The business has a staff of 65 split between its main facilities in Oxford and its wholly owned subsidiary in San Diego. Oxford Biomedica has corporate collaborations with Wyeth, Intervet, Amersham, Viragen, MolMed, Arius Research and Kiadis, and technology license agreements with Merck & Co and Biogen Idec. Robert James, director, coordinated the transaction for Prelude. The trust invested a total of £2.2m in Oxford Biomedica during 1998 and 2001

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland